JC-1 and Ferroptosis Research in Pulmonary Fibrosis
2026-10-05
JC-1 is a ratiometric fluorescent probe for studying mitochondrial membrane potential, but its signal is not a standalone diagnosis of apoptosis or ferroptosis. This overview places JC-1 within the preclinical evidence on low molecular weight fucoidan and pulmonary fibrosis, comparing mitochondrial, ferroptosis-related, histological and metabolomic findings while identifying important limitations.
Novel PDK4 Inhibitors for Metabolic Disease
2026-10-04
The 2019 Journal of Medicinal Chemistry study identified compound 8c as a promising allosteric pyruvate dehydrogenase kinase 4 inhibitor, with reported biochemical activity, favorable early drug-development properties, and effects in mouse models of metabolic and allergic disease. Its main contribution is a new anthraquinone-derived scaffold that links PDK4 inhibition with glucose tolerance, mast-cell biology, and cancer-related cellular phenotypes, while remaining preclinical.
GS967 and the Cardiac Late Sodium Current
2026-10-03
GS967 is a research compound described by APExBIO as a cardiac late sodium current inhibitor. This overview places the compound in the context of aging-related electrical and mechanical remodeling, with emphasis on findings from a 2024 study of Nav1.5 Ser571 phosphorylation. It distinguishes supplier-reported pharmacology from independently reported genetic evidence, compares conceptual applications in cardiac research, and outlines limitations affecting interpretation, translation, and evidence strength.
GS967: From Late INa to Cardiac Phenotype
2026-10-02
GS967 is a cardiac late sodium current inhibitor for connecting abnormal Nav1.5 activity with repolarization, calcium handling, and arrhythmia phenotypes. This article presents a causal, assay-oriented framework that extends beyond standard late INa workflows.
Repaglinide in Energy–DNA Repair Research
2026-10-01
Repaglinide is best understood as a glucose-regulatory pharmacological tool, not a validated ATG4B inhibitor. This article explains how to use it responsibly alongside the energy deficiency–DNA repair framework described in acute myeloid leukemia research.
Anagliptin (SK-0403): From DPP-4 to Vascular Biology
2026-10-01
Anagliptin (SK-0403) offers translational researchers a way to connect incretin biology with vascular smooth-muscle physiology. New rabbit-aorta data implicate Kv channel activation and SERCA pump function in vasorelaxation, creating a practical framework for mechanism-led diabetes and cardiovascular research.
Linagliptin (BI-1356) and Tau-Ser356 Research
2026-09-30
Linagliptin (BI-1356) is a DPP-4 inhibitor, whereas the cited tau study evaluated the NUAK1/2 inhibitor WZ4003. The evidence supports p-tau Ser356 as an Alzheimer’s disease-associated research endpoint, but it does not establish that linagliptin lowers p-tau Ser356.
Trelagliptin Succinate and Adipocyte Insulin Resistance
2026-09-30
The reference study shows that trelagliptin succinate can improve insulin resistance in differentiated 3T3-L1 adipocytes by enhancing IRS-1/PI-3K/AKT signaling, membrane-associated GLUT4, and glucose uptake. Its additional effects on free fatty acids and resistin suggest that DPP-4 inhibition may influence adipocyte endocrine function as well as glycemic regulation.
Anagliptin (SK-0403): Vascular Assay Workflow
2026-09-29
Anagliptin (SK-0403) supports a practical two-tier workflow spanning biochemical DPP-4 assays and ex vivo vascular physiology. Its reported Kv channel and SERCA-linked vasorelaxant profile makes it especially useful for connecting glycemic-control research with mechanistic cardiovascular studies.
Trifluoperazine 2HCl: From Target to Assay
2026-09-29
Trifluoperazine 2HCl is a potent dopamine D2 receptor inhibitor for mechanistic neuropharmacology and phenotypic research. This guide develops an assay-centered framework that separates direct receptor pharmacology from downstream ROS, autophagy, and cancer-model effects.
CD47 Blocks Phagocytosis by Limiting Vav Activation
2026-09-28
Miller et al. show that CD47 signaling suppresses macrophage phagocytosis by reducing Vav phosphorylation, interrupting a Rac-dependent route for engulfing antibody-coated targets. The study links this signaling change to a shift in phagocytic behavior and offers a framework for testing inhibitory signaling without assuming that all Rac-family members or Rac inhibitors are interchangeable.
From Lipid Oxidation to Osteoblast Ferroptosis
2026-09-27
A translational perspective on using BODIPY 581/591 C11 to measure membrane lipid oxidation in osteoblast ferroptosis studies, interpret NRF2/FSP1 findings, and strengthen assay design without overclaiming what a fluorescent readout can prove.
AZ 10417808 for ATRX-Deficient Glioma Assays
2026-09-26
Use AZ 10417808 as a pharmacologic probe in experiments testing whether ATRX status changes glioma-cell responses to receptor tyrosine kinase inhibition. A genotype-aware workflow can compare inhibitor response alone and with temozolomide while separating observed sensitivity from claims about mechanism or clinical benefit.
Trelagliptin Succinate in Diabetes and Cognition
2026-09-26
Trelagliptin succinate offers a selective DPP-4 inhibition strategy for studying glycemic control alongside diabetes-associated cognitive changes. This guide translates rat-model findings into practical target-engagement, cell, and behavioral workflows, with controls that help distinguish pathway effects from assay artifacts.
How NLG1 Proteolysis Sustains Social Memory
2026-09-25
A 2025 study links social interaction-induced Neuroligin 1 cleavage in the ventral hippocampus to cofilin-associated synaptic remodeling and the maintenance of short-term social memory. Its inhibition, deletion, and peptide-rescue experiments support a role for the NLG1 intracellular fragment, while leaving important questions about timing, cell specificity, and generalizability for future work.